On May 8th, the China Securities Regulatory Commission (CSRC) published a list of requirements for supplementary materials for overseas listing filings, covering the period from April 27th to May 8th, 2026. Among these, the CSRC has requested that Shenzhen Mindray Bio-Medical Electronics Co.,Ltd. (referred to as Mindray Medical, 300760.SZ) provide additional clarification on whether the intended use of the funds raised from this offering involves overseas investment and whether the relevant approval, verification, or filing procedures have been completed. As previously disclosed by the Hong Kong Stock Exchange on November 10th, 2025, Mindray Medical submitted an application for a main board listing in Hong Kong, with Huatai International and J.P. Morgan acting as joint sponsors.
Specifically, the CSRC has asked Mindray Medical to provide supplementary explanations on the following matters and has requested its legal counsel to verify and provide clear legal opinions: 1. Details regarding the development and operation of apps, mini-programs, and official accounts by the company and its subsidiaries, including whether they involve the collection and use of personal information. If so, the scale of user information collected and stored, as well as data usage practices, must be explained. 2. Clarification on whether the intended use of the funds raised involves overseas investment and confirmation of the completion of any necessary approval, verification, or filing procedures. 3. An explanation of the business activities and compliance status related to the "technology import and export" included in the business scope of the company and its subsidiaries. 4. Details on the specific fulfillment of regulatory procedures, such as overseas investment and foreign exchange registration, by the company's overseas subsidiaries, along with a conclusive opinion on their compliance. 5. Clarification on whether the business scope and actual operations of the company and its subsidiaries involve areas prohibited or restricted for foreign investment as outlined in the "Special Administrative Measures for Foreign Investment Access (Negative List) (2024 Edition)." 6. Specific details regarding the partial pledge of company shares held by the controlling shareholder, Magnifice (HK), and an assessment of its impact on the control rights of the company and its subsidiaries and the normal conduct of business.
According to its prospectus, Mindray Medical is a globally leading, innovation-driven world-class medical device enterprise and a leader in medical digitalization and intelligence. Data from Frost & Sullivan indicates that within China's medical device industry, the company's market capitalization in 2024 exceeded the combined total of the other major domestic leaders (ranked 2nd to 5th), and its industrial revenue was more than double that of the second-ranked company. The company has risen to become the 23rd largest global medical device enterprise, with its ranking continuously improving. It is the only Chinese company among the world's top 30 medical device firms and is one of the fastest-growing companies to achieve this status from its founding.
The company maintains a strategic layout, having established a comprehensive matrix covering multiple products and product lines. According to Frost & Sullivan, it is the only company among the world's top medical device enterprises that covers a wide range of diagnostic and treatment scenarios, including emergency rooms, operating rooms, intensive care units, general wards, as well as departments such as surgery, cardiology, laboratory, and ultrasound. Frost & Sullivan data also shows that based on 2024 revenue, the company holds a leading position in multiple sectors. It ranks among the top three globally in market share for six product categories and holds the number one market share position in China for nine product categories.